MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives

MaxCyte (NasdaqGS:MXCT) opened Q1 2026 with revenue of US$9.7 million and a basic EPS loss of US$0.04, while trailing 12 month figures show revenue of US$32.3 million and a basic EPS loss of US$0.37. The company has seen quarterly revenue move from US$10.4 million in Q1 2025 to US$9.7 million in Q1 2026, with net income moving from a loss of US$10.3 million to a loss of US$4.8 million over the same period. These figures frame the discussion for investors who are focused on how margins develop over time.

See our full analysis for MaxCyte.

With the headline numbers on the table, the next step is to set these results against the most widely discussed narratives around MaxCyte to see which views line up with the data and which start to look stretched.

See what the community is saying about MaxCyte

Losses Narrow, But Remain Heavy On A TTM Basis

• On a trailing 12 month basis, MaxCyte reported revenue of US$32.3 million and a net loss of US$39.1 million, compared with Q1 2026 quarterly revenue of US$9.7 million and a quarterly net loss of US$4.8 million.
• Bulls point out that revenue is forecast to grow about 18.3% a year. However, the latest trailing loss of US$39.1 million and five year loss growth of about 20.8% a year show that, so far, faster top line momentum has not translated into positive earnings.

Quarterly EPS Loss Has Shrunk Versus Recent History

• Basic EPS in Q1 2026 was a loss of US$0.04, compared with losses of about US$0.09 to US$0.12 per share across each quarter from Q2 2025 to Q4 2025, and a trailing 12 month EPS loss of US$0.37.
• Consensus narrative highlights a long runway of SPL programs and expected revenue growth of about 22.4% a year. Yet the fact that analysts still do not forecast profitability in the next three years and trailing EPS remains a US$0.37 loss underlines how dependent the medium term story is on margins improving from today’s levels.

Premium 3.6x P/S With Ongoing Unprofitability

• MaxCyte trades on a trailing P/S of 3.6x, above the peer average of 2.7x and slightly above the US Life Sciences industry at 3.4x, while the company is still loss making over the trailing 12 months.
• Bears argue that paying a premium multiple is hard to justify when forecasts still show losses over the next three years, and the trailing net loss of US$39.1 million alongside a share price of US$1.09 means investors are currently accepting both a higher P/S and a history of widening losses relative to the last five years.

Skeptics who see rich sales multiples and no near term path to profit may want to read the detailed cautious case for how this could play out for margins and royalties 🐻 MaxCyte Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for MaxCyte on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views on growth, losses and valuation in play, it makes sense to review the underlying data and stress test your own thesis quickly. To weigh up both the upside potential and the concerns that others are flagging, start by checking the 1 key reward and 1 important warning sign.

See What Else Is Out There

MaxCyte is still carrying heavy losses on a trailing basis and trades on a premium 3.6x P/S while forecasts do not yet point to near term profitability.

If you are uncomfortable with ongoing losses and a richer sales multiple, it makes sense to compare this setup with companies screened as 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com